No Data
No Data
6-K: Report of foreign private issuer (related to financial reporting)
Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech Advances Cancer Trials, Strengthening 2025 Pipeline
Oncolytics Biotech Continues To Make Good Progress In 2025 With Key Regulatory And Clinical Advancements, Reinforcing Pelareorep's Potential In Hard-to-treat Cancers
Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study
Oncolytics Biotech Brief: SAys Strengthening Its Pipeline in 2025